Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2022-07, Vol.2022, p.1-6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 2022 |
| creator | El-Senosy, Fatma M. Abd El Aziz, Rasha Elsayed Mohamed Kasim, Sammar Ahmed Gad, Lamia Abdulbary Hassan, Donia Ahmed Sabry, Seham El mancy, Ismail Mohamed Shawky, Taiseer Ahmed Mohamed, Ibrahim Ghounim Ramadan Elmonier, Rady Kotb, Essam Abdul-Mohymen, Abeer Mohammed |
| description | Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. Subjects and Methods. The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. Results. HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p |
| doi_str_mv | 10.1155/2022/4524637 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3103513741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-28b7d8599f922486eb0bcab9cbadacd97cad33df51be070f8d4e04a51cce2cb73</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0Eoh9w4wdY4oJUQv0RJ_EFqVpaQKwEYuFsje1J4yrrtHbSqv8eL7tCggMX29I8fjQzLyGvOHvHuVLngglxXitRN7J9Qo55W4uKi5o_LW_ZdJVikh-Rk5xvGBNKdew5OZJKy4Y16pjcbTAtW3oZ_eQg0jXe45gpRE83i3VjiMHBSC_mAdOU3bg7Q6Yh0m8wB4xzpg9hHuhqSFNB6ZfgIz7-_l-U1WaGa6TfMRbHh5ARMuYX5FkPY8aXh_uU_Ly6_LH6VK2_fvy8ulhXTio1V6Kzre-U1r0Wou4atMw6sNpZ8OC8bh14KX2vuEXWsr7zNbIaFHcOhbOtPCXv997bxW7Ru9JsgtHcprCF9GgmCObvSgyDuZ7ujZaMSdUVwZuDIE13C-bZbEN2OI4QcVqyEY3WWnVCq4K-_ge9mZZUps5G8iLjsq15od7uKVe2mBP2f5rhzOyyNLsszSHLgp_t8SFEDw_h__QvKeSerg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3103513741</pqid></control><display><type>article</type><title>Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>El-Senosy, Fatma M. ; Abd El Aziz, Rasha Elsayed Mohamed ; Kasim, Sammar Ahmed ; Gad, Lamia Abdulbary ; Hassan, Donia Ahmed ; Sabry, Seham ; El mancy, Ismail Mohamed ; Shawky, Taiseer Ahmed ; Mohamed, Ibrahim Ghounim Ramadan ; Elmonier, Rady ; Kotb, Essam ; Abdul-Mohymen, Abeer Mohammed</creator><contributor>Chen, Tun-Chieh ; Tun-Chieh Chen</contributor><creatorcontrib>El-Senosy, Fatma M. ; Abd El Aziz, Rasha Elsayed Mohamed ; Kasim, Sammar Ahmed ; Gad, Lamia Abdulbary ; Hassan, Donia Ahmed ; Sabry, Seham ; El mancy, Ismail Mohamed ; Shawky, Taiseer Ahmed ; Mohamed, Ibrahim Ghounim Ramadan ; Elmonier, Rady ; Kotb, Essam ; Abdul-Mohymen, Abeer Mohammed ; Chen, Tun-Chieh ; Tun-Chieh Chen</creatorcontrib><description>Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. Subjects and Methods. The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. Results. HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p<0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. Conclusions. Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1155/2022/4524637</identifier><identifier>PMID: 35936065</identifier><language>eng</language><publisher>London: Hindawi</publisher><subject>Angiogenesis ; Arteriosclerosis ; Atherosclerosis ; Blood platelets ; Body mass index ; Cardiovascular disease ; Cell activation ; Cholesterol ; Chronic illnesses ; Correlation analysis ; Creatinine ; End-stage renal disease ; Endothelial cells ; Endothelium ; Hemodialysis ; Kidney diseases ; Laboratories ; Parathyroid hormone ; Triglycerides ; Tumor necrosis factor-TNF ; Uric acid</subject><ispartof>International journal of clinical practice (Esher), 2022-07, Vol.2022, p.1-6</ispartof><rights>Copyright © 2022 Fatma M. El-Senosy et al.</rights><rights>Copyright © 2022 Fatma M. El-Senosy et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Fatma M. El-Senosy et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-28b7d8599f922486eb0bcab9cbadacd97cad33df51be070f8d4e04a51cce2cb73</citedby><cites>FETCH-LOGICAL-c355t-28b7d8599f922486eb0bcab9cbadacd97cad33df51be070f8d4e04a51cce2cb73</cites><orcidid>0000-0002-5506-3039</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300358/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300358/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,873,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>Chen, Tun-Chieh</contributor><contributor>Tun-Chieh Chen</contributor><creatorcontrib>El-Senosy, Fatma M.</creatorcontrib><creatorcontrib>Abd El Aziz, Rasha Elsayed Mohamed</creatorcontrib><creatorcontrib>Kasim, Sammar Ahmed</creatorcontrib><creatorcontrib>Gad, Lamia Abdulbary</creatorcontrib><creatorcontrib>Hassan, Donia Ahmed</creatorcontrib><creatorcontrib>Sabry, Seham</creatorcontrib><creatorcontrib>El mancy, Ismail Mohamed</creatorcontrib><creatorcontrib>Shawky, Taiseer Ahmed</creatorcontrib><creatorcontrib>Mohamed, Ibrahim Ghounim Ramadan</creatorcontrib><creatorcontrib>Elmonier, Rady</creatorcontrib><creatorcontrib>Kotb, Essam</creatorcontrib><creatorcontrib>Abdul-Mohymen, Abeer Mohammed</creatorcontrib><title>Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases</title><title>International journal of clinical practice (Esher)</title><description>Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. Subjects and Methods. The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. Results. HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p<0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. Conclusions. Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.</description><subject>Angiogenesis</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Blood platelets</subject><subject>Body mass index</subject><subject>Cardiovascular disease</subject><subject>Cell activation</subject><subject>Cholesterol</subject><subject>Chronic illnesses</subject><subject>Correlation analysis</subject><subject>Creatinine</subject><subject>End-stage renal disease</subject><subject>Endothelial cells</subject><subject>Endothelium</subject><subject>Hemodialysis</subject><subject>Kidney diseases</subject><subject>Laboratories</subject><subject>Parathyroid hormone</subject><subject>Triglycerides</subject><subject>Tumor necrosis factor-TNF</subject><subject>Uric acid</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNp9kU1v1DAQhi0Eoh9w4wdY4oJUQv0RJ_EFqVpaQKwEYuFsje1J4yrrtHbSqv8eL7tCggMX29I8fjQzLyGvOHvHuVLngglxXitRN7J9Qo55W4uKi5o_LW_ZdJVikh-Rk5xvGBNKdew5OZJKy4Y16pjcbTAtW3oZ_eQg0jXe45gpRE83i3VjiMHBSC_mAdOU3bg7Q6Yh0m8wB4xzpg9hHuhqSFNB6ZfgIz7-_l-U1WaGa6TfMRbHh5ARMuYX5FkPY8aXh_uU_Ly6_LH6VK2_fvy8ulhXTio1V6Kzre-U1r0Wou4atMw6sNpZ8OC8bh14KX2vuEXWsr7zNbIaFHcOhbOtPCXv997bxW7Ru9JsgtHcprCF9GgmCObvSgyDuZ7ujZaMSdUVwZuDIE13C-bZbEN2OI4QcVqyEY3WWnVCq4K-_ge9mZZUps5G8iLjsq15od7uKVe2mBP2f5rhzOyyNLsszSHLgp_t8SFEDw_h__QvKeSerg</recordid><startdate>20220713</startdate><enddate>20220713</enddate><creator>El-Senosy, Fatma M.</creator><creator>Abd El Aziz, Rasha Elsayed Mohamed</creator><creator>Kasim, Sammar Ahmed</creator><creator>Gad, Lamia Abdulbary</creator><creator>Hassan, Donia Ahmed</creator><creator>Sabry, Seham</creator><creator>El mancy, Ismail Mohamed</creator><creator>Shawky, Taiseer Ahmed</creator><creator>Mohamed, Ibrahim Ghounim Ramadan</creator><creator>Elmonier, Rady</creator><creator>Kotb, Essam</creator><creator>Abdul-Mohymen, Abeer Mohammed</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5506-3039</orcidid></search><sort><creationdate>20220713</creationdate><title>Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases</title><author>El-Senosy, Fatma M. ; Abd El Aziz, Rasha Elsayed Mohamed ; Kasim, Sammar Ahmed ; Gad, Lamia Abdulbary ; Hassan, Donia Ahmed ; Sabry, Seham ; El mancy, Ismail Mohamed ; Shawky, Taiseer Ahmed ; Mohamed, Ibrahim Ghounim Ramadan ; Elmonier, Rady ; Kotb, Essam ; Abdul-Mohymen, Abeer Mohammed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-28b7d8599f922486eb0bcab9cbadacd97cad33df51be070f8d4e04a51cce2cb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiogenesis</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Blood platelets</topic><topic>Body mass index</topic><topic>Cardiovascular disease</topic><topic>Cell activation</topic><topic>Cholesterol</topic><topic>Chronic illnesses</topic><topic>Correlation analysis</topic><topic>Creatinine</topic><topic>End-stage renal disease</topic><topic>Endothelial cells</topic><topic>Endothelium</topic><topic>Hemodialysis</topic><topic>Kidney diseases</topic><topic>Laboratories</topic><topic>Parathyroid hormone</topic><topic>Triglycerides</topic><topic>Tumor necrosis factor-TNF</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Senosy, Fatma M.</creatorcontrib><creatorcontrib>Abd El Aziz, Rasha Elsayed Mohamed</creatorcontrib><creatorcontrib>Kasim, Sammar Ahmed</creatorcontrib><creatorcontrib>Gad, Lamia Abdulbary</creatorcontrib><creatorcontrib>Hassan, Donia Ahmed</creatorcontrib><creatorcontrib>Sabry, Seham</creatorcontrib><creatorcontrib>El mancy, Ismail Mohamed</creatorcontrib><creatorcontrib>Shawky, Taiseer Ahmed</creatorcontrib><creatorcontrib>Mohamed, Ibrahim Ghounim Ramadan</creatorcontrib><creatorcontrib>Elmonier, Rady</creatorcontrib><creatorcontrib>Kotb, Essam</creatorcontrib><creatorcontrib>Abdul-Mohymen, Abeer Mohammed</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Senosy, Fatma M.</au><au>Abd El Aziz, Rasha Elsayed Mohamed</au><au>Kasim, Sammar Ahmed</au><au>Gad, Lamia Abdulbary</au><au>Hassan, Donia Ahmed</au><au>Sabry, Seham</au><au>El mancy, Ismail Mohamed</au><au>Shawky, Taiseer Ahmed</au><au>Mohamed, Ibrahim Ghounim Ramadan</au><au>Elmonier, Rady</au><au>Kotb, Essam</au><au>Abdul-Mohymen, Abeer Mohammed</au><au>Chen, Tun-Chieh</au><au>Tun-Chieh Chen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><date>2022-07-13</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. Subjects and Methods. The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. Results. HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p<0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. Conclusions. Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.</abstract><cop>London</cop><pub>Hindawi</pub><pmid>35936065</pmid><doi>10.1155/2022/4524637</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-5506-3039</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2022-07, Vol.2022, p.1-6 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300358 |
| source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Angiogenesis Arteriosclerosis Atherosclerosis Blood platelets Body mass index Cardiovascular disease Cell activation Cholesterol Chronic illnesses Correlation analysis Creatinine End-stage renal disease Endothelial cells Endothelium Hemodialysis Kidney diseases Laboratories Parathyroid hormone Triglycerides Tumor necrosis factor-TNF Uric acid |
| title | Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A46%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Endocan%20Levels%20and%20Subclinical%20Atherosclerosis%20in%20Patients%20with%20Chronic%20Kidney%20and%20End-Stage%20Renal%20Diseases&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=El-Senosy,%20Fatma%20M.&rft.date=2022-07-13&rft.volume=2022&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1155/2022/4524637&rft_dat=%3Cproquest_pubme%3E3103513741%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3103513741&rft_id=info:pmid/35936065&rfr_iscdi=true |